Týdenní vs dvoutýdenní aplikace cetuximabu v léčbě metastatického kolorektálního karcinomu – aktuální klinická data

Česká verzia

Authors: R. Němeček
Authors place of work: Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Published in the journal: Klin Onkol 2013; 26(4): 291-293
Category: Oncology Highlights

Článek byl podpořen firmou Merck Serono.

Zdroje

1. Nolting A, Fox FE, Kovar A. Clinical drug development of cetuximab, a monoclonal antibody. In: Meibohm B (ed). Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies In Drug Development. Weinheim, Germany: Wiley VCH Verlag GmbH & Co. KGaA 2006: 353– 371.

2. Fracasso PM, Burris H 3rd, Arquette MA et al. A phase 1 escalating single‑dose and weekly fixed‑dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 2007; 13(3): 986– 993.

3. Tabernero J, Ciardiello F, Rivera F et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two‑part pharmacokinetic/ pharmacodynamic phase I dose‑escalation study. Ann Oncol 2010; 21(7): 1537– 1545.

4. Martin‑Martorell P, Rosello S, Rodriguez‑ Braun E et al. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br J Cancer 2008; 99(3): 455– 458.

5. Pfeiffer P, Nielsen D, Bjerregaard J et al. Biweekly cetuximab and irinotecan as third‑line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008; 19(6): 1141– 1145.

6. Shitara K, Yuki S, Yoshida M et al. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild‑type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Invest New Drugs 2012; 30(2): 787– 793.

7. Kang MJ, Hong YS, Kim KP et al. Biweekly cetuximab plus irinotecan as secondline chemotherapy for patients with irinotecan‑ refractory and KRAS wild‑type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs 2012; 30(4): 1607– 1613.

8. Jensen BV, Schou JV, Johannesen HH et al. Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5- FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy. J Clin Oncol 2010; 28 (Suppl): 7.

9. Bouchahda M, Macarulla T, Liedo G et al. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol 2011; 28 (Suppl 1): S253– S258.

10. Roca JM, Alonso V, Pericay C et al. Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer. Chemotherapy 2010; 56(2): 142– 146.

11. Brodowicz T, Ciuleanu TE, Radosavljevic D et al. FOLFOX4 plus cetuximab administered weekly or every second week in the first‑line treatment of patients with KRAS wild‑type metastatic colorectal cancer: a randomized phase II CECOG study. Ann Oncol 2013; 24(7): 1769– 1777.

12. Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX‑ 4 as first‑line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22(7): 1535– 1546.

13. Van Cutsem E, Köhne CH, Láng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first‑line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29(15): 2011– 2019.